Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Can BridgeBio’s Attruby narrow Pfizer’s Vyndamax lead in the ATTR-CM market?

Pfizer owns the ATTR-CM legacy. BridgeBio now has data that could test whether clinical differentiation can move prescribing habits.

Read More
Pharma & Biotech

Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset

Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.

Read More
Pharma & Biotech

Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin

China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.

Read More
Pharma & Biotech

Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?

ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.

Read More
Pharma & Biotech

Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data

Spasticity care is not one injection cycle. Merz Therapeutics is pushing XEOMIN data toward durability, dosing flexibility and patient goals.

Read More
Representative image of oncology specialists reviewing head and neck cancer scans in a Saudi clinical setting, reflecting CEL-SCI Corporation’s Multikine partnership with Amarox and its potential regulatory pathway for cancer immunotherapy in Saudi Arabia.
Pharma & Biotech

Can CEL-SCI’s Saudi Arabia deal turn Multikine into a real commercial oncology test?

Multikine still awaits a commercial breakthrough. CEL-SCI’s Saudi deal tests whether regional oncology access can change that trajectory.

Read More
Avenacy expands critical injectable portfolio with tranexamic acid in sodium chloride
Pharma & Biotech

Why Avenacy’s 27th injectable launch could matter more than its modest market size suggests

Injectable safety is becoming a workflow battle. Avenacy’s tranexamic acid launch tests demand for ready-to-use hospital formats.

Read More
Representative image of circular RNA-based in vivo CAR-T research in a biotechnology laboratory, highlighting Therorna’s TI-0032 program and the growing push to make cell therapy more scalable for autoimmune disease treatment.
Pharma & Biotech

Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?

CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.

Read More
Representative image of anchored monoclonal antibody immunotherapy targeting the cancer tumor microenvironment, illustrating how Ankyra Therapeutics’ preclinical platform aims to improve local drug retention while reducing systemic toxicity.
Pharma & Biotech

Ankyra Therapeutics targets a bigger immunotherapy problem with anchored monoclonal antibodies

Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More